Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Neurodegener Dis Manag ; 7(5): 299-306, 2017 Oct.
Article in English | MEDLINE | ID: mdl-29043907

ABSTRACT

AIM: This cross-sectional study aimed to evaluate the prescription pattern, awareness of disease and treatment in patients with Parkinson's disease (PD). MATERIALS & METHODS: A total of 100 PD patients, attending a tertiary care hospital in Mumbai were included. Prescriptions were analyzed and awareness was evaluated using a questionnaire. RESULTS: The mean number of anti-Parkinson agents (APA) prescribed was 1.52 ± 0.65. Number of APA strongly correlated with disease duration (ρ = 0.818; p < 0.001). Many APA were underutilized (prescribed daily dose/defined daily dose < 1). There was no awareness of all items on symptoms and alternative therapeutic options. Awareness of disease impairments (32%), long-term complications (28%), dosing regimen (46%) and follow-up (36%) was poor. CONCLUSION: More than one APA is commonly prescribed in PD patients. Awareness of disease and treatment of PD is poor among the patients.


Subject(s)
Antiparkinson Agents/therapeutic use , Health Knowledge, Attitudes, Practice , Parkinson Disease/drug therapy , Parkinson Disease/psychology , Practice Patterns, Physicians' , Aftercare , Aged , Awareness , Cross-Sectional Studies , Drug Therapy, Combination , Female , Humans , Linear Models , Male , Middle Aged , Polypharmacy , Socioeconomic Factors , Surveys and Questionnaires
2.
J Empir Res Hum Res Ethics ; 11(3): 267-73, 2016 07.
Article in English | MEDLINE | ID: mdl-27353243

ABSTRACT

The Indian regulations for clinical trials were amended in January 2013 regarding reporting time lines, relatedness, and compensation for Serious Adverse Events (SAEs). Our study assessed the extent of regulatory compliance in reporting SAEs to the Institutional Ethics Committee (IEC) over 4 years (January 2009-January 2013) before and 18 months after (February 2013-July 2014) the amended regulations. SAE reports were studied retrospectively for reporting time lines, relatedness, compensation, and IEC response before and after the law revision. Before 2013 had 89/160 (55.6%) SAEs reports submitted late while in the after period, only 2/11 reports were delayed (18%). In the before period, 26 SAE reports mentioned "relatedness" of which only 15 (57.6%) stated about compensation. After 2013, all the 9 non-death reports were complete. The IEC took median 17 days to respond before 2013, while after 2013 responded within 5 days. Thus, there was poor compliance in terms of SAE reporting time lines before the revision of the law.


Subject(s)
Biomedical Research/ethics , Drug-Related Side Effects and Adverse Reactions , Ethics Committees , Guideline Adherence , Patient Safety/legislation & jurisprudence , Social Control, Formal , Tertiary Care Centers , Biomedical Research/legislation & jurisprudence , Compensation and Redress , Humans , India , Legislation, Medical
SELECTION OF CITATIONS
SEARCH DETAIL
...